Article
Inhibition and degradation of NRAS with a pan-NRAS monobody.
Oncogene - 1 Nov 2024
Whaby Michael, Ketavarapu Gayatri, Koide Akiko, Mazzei Megan, Mintoo Mubashir, Glasser Eliezra, Patel Unnatiben, Nasarre Cecile, Sale Matthew J, McCormick Frank, Koide Shohei, O'Bryan John P
Abstract excerpt
The RAS family GTPases are the most frequently mutated oncogene family in human cancers. Activating mutations in either of the three RAS isoforms (HRAS, KRAS, or NRAS) are found in nearly 20% of all human tumors with NRAS mutated in ~25% of melanomas. Despite remarkable advancements in therapies targeted against mutant KRAS, NRAS-specific pharmacologics are lacking. Thus, development of inhibitors of NRAS would...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.